CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has reported Other Non-Current Liabilities for 12 years, with the latest figure at $5.9 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 79.16% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 79.16% YoY) and the FY2025 annual result came in at $6.1 million, up 78.34% from the prior year.
• Other Non-Current Liabilities eased to $5.9 million in Q1 2026 per CRSP's latest filing, from $6.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $7.3 million in Q1 2022 and troughed at $958000.0 in Q4 2023.
• A 5-year average of $4.8 million and a median of $5.3 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities sank 83.95% in 2023, then soared 259.5% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $6.0 million in 2022, then tumbled by 83.95% to $958000.0 in 2023, then jumped by 259.5% to $3.4 million in 2024, then surged by 78.34% to $6.1 million in 2025, then slipped by 3.16% to $5.9 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.9 million, $6.1 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.